NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $9.00 to $14.00. They now have an "overweight" rating on the stock.
NeuroPace to Host Investor Day on January 28th in New York City
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting